Sign in

    Kenneth Atkins

    Research Analyst at Cowen & Company

    Kenneth Atkins's questions to Kezar Life Sciences (KZR) leadership

    Kenneth Atkins's questions to Kezar Life Sciences (KZR) leadership • Q2 2020

    Question

    Kenneth Atkins of Cowen & Company asked for elaboration on why a 50% reduction in proteinuria is a clinically meaningful endpoint for lupus nephritis and questioned the reasons behind the high screen failure rate and discontinuation of the MARINA study.

    Answer

    Chief Medical Officer Noreen Henig explained that a 50% proteinuria reduction is a standard clinical trial endpoint that correlates with long-term benefit. Regarding the MARINA study, she clarified it was withdrawn because its highly selective inclusion criteria did not reflect real-world patients, resulting in zero enrollments. The decision was not based on new clinical data but on the need for a revised, more inclusive protocol.

    Ask Fintool Equity Research AI

    Kenneth Atkins's questions to Kezar Life Sciences (KZR) leadership • Q2 2020

    Question

    Kenneth Atkins of Cowen and Company sought clarification on the clinical significance of the 50% proteinuria reduction endpoint for the MISSION trial and inquired about the reasons for the MARINA study's discontinuation and high screen failure rate.

    Answer

    Chief Medical Officer Noreen Henig explained that a 50% proteinuria reduction is a standard, clinically meaningful endpoint in lupus nephritis trials, used to benchmark against existing studies. She also clarified that the MARINA study was withdrawn due to overly restrictive enrollment criteria that led to zero patient enrollments, an issue not seen in other trials, and the protocol will be redesigned.

    Ask Fintool Equity Research AI